SCHEMBL12437331

SCHEMBL12437331

CCCCCCN1CCC(Oc2ccc(C(=O)NCCCN3CCCC3)cc2Cl)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC5A7 Q9GZV3 1/20 0.54
HSD17B10 Q99714 2/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
F10 P00742 1/20 0.49
UTS2R Q9UKP6 1/20 0.48
CCR2 P41597 1/20 0.48
DRD2 P14416 2/20 0.48
DRD3 P35462 2/20 0.48
DRD4 P21917 1/20 0.48
SMYD2 Q9NRG4 1/20 0.48
KMT2A Q03164 3/20 0.47
HRH3 Q9Y5N1 2/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
MEN1 O00255 2/20 0.47
CCR3 P51677 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437332 0.86 UTS2R (0.55) SLC5A7ALDH1A1LMNAKDM4EUTS2R
SCHEMBL12437337 0.85 ALDH1A1 (0.58) SLC5A7HSD17B10ALDH1A1LMNAKDM4E
SCHEMBL12437330 0.85 SMYD2 (0.51) SLC5A7ALDH1A1KDM4EF10UTS2R
SCHEMBL12437349 0.84 SLC5A7 (0.53) SLC5A7ALDH1A1LMNAF10DRD2
SCHEMBL14147057 0.84 GAA (0.58) SLC5A7HSD17B10ALDH1A1LMNAGAA
SCHEMBL12437352 0.84 SLC5A7 (0.49) SLC5A7ALDH1A1LMNAF10DRD2
SCHEMBL12437957 0.84 SLC5A7 (0.51) SLC5A7ALDH1A1KDM4EF10CCR2
SCHEMBL12437336 0.83 SLC5A7 (0.50) SLC5A7ALDH1A1CCR2DRD2DRD3
SCHEMBL12513958 0.83 SLC6A2 (0.54) SLC5A7ALDH1A1KDM4EUTS2RDRD2
SCHEMBL13925104 0.83 SLC5A7 (0.52) SLC5A7ALDH1A1LMNAF10UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD SLC5A7 4329/4885HSD17B10 988/4885ALDH1A1 591/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD SLC5A7 4329/4885HSD17B10 988/4885ALDH1A1 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.